CJC-1295 No Dac ( 5mg ) + Ipamorelin ( 5mg ) Blend 10mg

Description

CJC-1295 & Ipamorelin Blend – 2 peptides, 1 vial

Contains CJC 1295 no DAC 5mg & Ipamorelin 5mg – Premium Research Peptide

CJC-1295 + Ipamorelin Blend 10mg – Research Peptide

CJC-1295 + Ipamorelin Blend is a dual-peptide formulation containing CJC-1295 and Ipamorelin, two compounds investigated for their interactions with growth hormone signalling pathways.

CJC-1295 is a growth hormone-releasing hormone (GHRH) analogue, while Ipamorelin is a selective growth hormone secretagogue receptor agonist. Together, these peptides are studied in laboratory research involving growth hormone secretion and receptor signalling.

CJC-1295 + Ipamorelin Blend 10mg – Research Peptide

The CJC-1295 + Ipamorelin Blend 10mg combines two synthetic research peptides investigated for their roles in growth hormone regulation and endocrine signalling. This dual-peptide formulation contains 5mg CJC-1295 (No DAC) and 5mg Ipamorelin, providing researchers with two compounds that interact with distinct biological pathways associated with growth hormone secretion.

CJC-1295 is a growth hormone-releasing hormone (GHRH) analogue, while Ipamorelin is a selective growth hormone secretagogue receptor agonist. Their different mechanisms make them relevant to experimental investigations of growth hormone signalling.

What Is CJC-1295 (No DAC)?

CJC-1295 (No DAC) is commonly used in the research peptide market to describe a modified growth hormone-releasing hormone analogue without a drug affinity complex.

GHRH analogues are investigated for their ability to interact with receptors involved in growth hormone release from the anterior pituitary gland.

Research areas include:

• Growth hormone-releasing hormone receptor activity
• Pituitary signalling pathways
• Endocrine feedback mechanisms
• Growth hormone secretion dynamics

The No DAC designation distinguishes this formulation from long-acting CJC-1295 preparations containing a drug affinity complex.

What Is Ipamorelin?

Ipamorelin is a synthetic pentapeptide investigated for its activity at the growth hormone secretagogue receptor (GHSR-1a).

Unlike CJC-1295, which acts through the GHRH receptor pathway, Ipamorelin interacts with a receptor associated with ghrelin signalling.

Laboratory investigations have explored:

• Growth hormone secretagogue receptor activation
• Pituitary growth hormone release
• Receptor selectivity
• Interactions between ghrelin-related and GHRH signalling pathways

CJC-1295 vs Ipamorelin: Understanding the Differences

Although both compounds are studied in connection with growth hormone secretion, they operate through different receptor systems.

Feature	CJC-1295 (No DAC)	Ipamorelin
Peptide type	GHRH analogue	Synthetic pentapeptide
Primary receptor	GHRH receptor	GHSR-1a
Research focus	GHRH signalling	Ghrelin-related signalling
Mechanism	GHRH receptor agonism	Growth hormone secretagogue receptor agonism

These distinctions are important when investigating different mechanisms involved in endocrine regulation.

Why Are CJC-1295 and Ipamorelin Studied Together?

The combination is of research interest because GHRH receptor signalling and growth hormone secretagogue receptor signalling represent separate mechanisms involved in regulating growth hormone release.

Investigating both pathways may help researchers examine receptor interactions, intracellular signalling and endocrine responses under controlled experimental conditions.

However, the presence of both compounds in a formulation does not itself establish superior efficacy, safety or synergistic effects. Such conclusions require appropriately designed studies.

Product Specifications

• Product: CJC-1295 + Ipamorelin Blend
• Total peptide content: 10mg
• Composition: 5mg CJC-1295 (No DAC) + 5mg Ipamorelin
• Form: Lyophilised powder
• Research category: Growth Factor Research
• Quality documentation: Batch-specific Certificate of Analysis (COA), where available